Repligen Corporation to Present at Upcoming Investor Conferences
25 mai 2022 07h30 HE
|
Repligen Corporation
WALTHAM, Mass., May 25, 2022 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will be...
Repligen Reports First Quarter 2022 Financial Results and Updates Full Year 2022 Financial Guidance
27 avr. 2022 07h30 HE
|
Repligen Corporation
—Record revenue of $206.4 million for the quarter, and year-over-year growth of 45% as reported and 48% at constant currency —Organic revenue growth of 44% for the quarter and base...
Repligen to Report First Quarter 2022 Financial Results
13 avr. 2022 07h30 HE
|
Repligen Corporation
WALTHAM, Mass., April 13, 2022 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report its first quarter 2022 financial results on Wednesday, April 27,...
Repligen Corporation to Present at KeyBanc Life Science and MedTech Investor Forum
18 mars 2022 07h30 HE
|
Repligen Corporation
WALTHAM, Mass., March 18, 2022 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will present...
Repligen Reports Fourth Quarter and Full Year 2021 Financial Results
17 févr. 2022 07h30 HE
|
Repligen Corporation
— Record revenue of $186.5 million for the quarter, and year-over-year growth of 72% — Record revenue of $670.5 million for the year, and year-over-year growth of 83% — Organic...
Repligen Launches AAV Affinity Resins for Gene Therapy Purification
15 févr. 2022 07h30 HE
|
Repligen Corporation
WALTHAM, Mass., Feb. 15, 2022 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced the commercial launch of...
Repligen Corporation to Present at 11th Annual SVB Leerink Healthcare Conference
11 févr. 2022 07h30 HE
|
Repligen Corporation
WALTHAM, Mass., Feb. 11, 2022 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will present...
Repligen to Report Fourth Quarter and Full Year 2021 Financial Results
03 févr. 2022 09h30 HE
|
Repligen Corporation
WALTHAM, Mass., Feb. 03, 2022 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report its fourth quarter and full year 2021 financial results on Thursday,...
Repligen Corporation to Present at 40th Annual J.P. Morgan Healthcare Conference
30 déc. 2021 07h30 HE
|
Repligen Corporation
WALTHAM, Mass., Dec. 30, 2021 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will present...
Repligen Corporation to Present at Upcoming Investor Conferences
12 nov. 2021 07h30 HE
|
Repligen Corporation
WALTHAM, Mass., Nov. 12, 2021 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will present at...